NASDAQ · STOCK
Halozyme
$82.53
52W $58.53 – $84.44
51/100
$9.79B
28.3
0.84
Is HALO Bullish or Bearish?
Mixed.
Innellis AI committee rates Halozyme (HALO) Watch with a composite score of 51/100
, based on 7 analysts with 57% agreement.
Last updated July 31, 2026.
What Would Change This View
- Upgrade to Buy
- Requires a committee score of 60.0 — +8.63 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Reduce
- Requires the score to fall below 40.0 — -11.37 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 39.1% yoy -- genuine top-line momentum. Risk Analyst remains cautious — high leverage (debt-to-equity 43.89) amplifies downside in a stress scenario. This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- ROE of 126.3% shows genuine earnings power backing the valuation — Value
- Revenue growing 39.1% YoY -- genuine top-line momentum — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- P/E of 27.9 is moderate-to-rich — Value
- Price-to-book of 162.1x prices in significant intangible value — Value
- Debt-to-equity of 43.89 adds balance-sheet risk to the value case — Value
- EPS declining -26.2% YoY despite any revenue growth — Growth
- RSI at 73 is in overbought territory — Technical
- High leverage (debt-to-equity 43.89) amplifies downside in a stress scenario — Risk
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of July 31, 2026
Overall Committee Score
51/100
Agreement
57%
Analysts
7
Conviction
Contested
Sector Rank
Top 78%
of 93 Healthcare peers
Value Analyst
neutral
45
/ 100 · High confidence
Fair value -- neither a bargain nor obviously overpriced
+ ROE of 126.3% shows genuine earnings power backing the valuation
− P/E of 27.9 is moderate-to-rich
Growth Analyst
bullish
63
/ 100 · High confidence
Strong, accelerating growth with consistent execution
+ Revenue growing 39.1% YoY -- genuine top-line momentum
− EPS declining -26.2% YoY despite any revenue growth
Technical Analyst
bullish
61
/ 100 · High confidence
Price action is constructive -- trend and momentum agree
+ Price structure making higher highs and higher lows
− RSI at 73 is in overbought territory
Risk Analyst
bearish
30
/ 100 · Low confidence
Elevated risk from leverage, volatility, event exposure, or portfolio concentration -- size accordingly
− High leverage (debt-to-equity 43.89) amplifies downside in a stress scenario
Macro Analyst
neutral
58
/ 100 · Moderate confidence
Macro backdrop is mixed or neutral -- not a strong tailwind or headwind either way
+ Market regime is bullish (Bull market -- normal position sizing)
News Analyst
neutral
58
/ 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager
neutral
45
/ 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 2744.14)
Investment Thesis Evolution
Committee score moved marginally from 52.4 to 51.4.
- Committee agreement increased notably from 43% to 57%.
- New bearish signals: 2 appeared.
- New bullish signals: 1 appeared.
- Bearish pressure eased: 2 signal(s) disappeared.
- Analyst(s) changed stance: Macro Analyst.
Analyst-level changes:
- Macro Analyst: stance bullish->neutral; score 65->58 (-8); +1 bullish signal(s).
- Portfolio Manager: +2 bearish signal(s).
Comparing 2026-07-30 to 2026-07-31 (1 day apart).
Technical Analysis
RSI (14)
65.4
Neutral
MACD Histogram
0.232
Bullish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Hh Hl
Bollinger %B
0.77
Inside Bands
Price vs Moving Averages
EMA 9
$81.58
Above
EMA 21
$79.31
Above
EMA 50
$75.58
Above
EMA 200
$69.92
Above
Fundamental Analysis
Valuation
49
Growth
48
Profitability
9
Financial Health
50
Cash Flow
37
Valuation
P/E Ratio
28.3×
P/B Ratio
44.40×
PEG Ratio
-1.17
Dividend Yield
0.00%
52W High
$84.44
52W Low
$58.53
Quality & Growth
ROE
649.2%
ROA
12.6%
Gross Margin
76.9%
Operating Margin
57.0%
Revenue Growth YoY
—
Debt / Equity
9.76
AI Fundamental Assessment
P/E ratio of 28.3 (moderate relative to a 15-40x range); Price-to-book of 44.4x; PEG ratio of -1.2 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 6.5%; Return on assets of 0.1%; Net margin of 0.2%; Gross margin of 0.8%; Current ratio of 2.76 (healthy short-term liquidity); Debt-to-equity of 9.76; Free cash flow margin of 1.0% (thin cash generation); Free cash flow per share is positive (5.65); Most recent quarter beat estimates by 2.5%; EPS growth accelerating (-114.0% -> +766.7% QoQ); Analyst estimates falling over recent quarters
Get the Full HALO Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →